Corneal Endothelial
Cell Therapy

Our initial candidate aims to treat dystrophies that cause corneal blindness.

Healthy cells from a donor cornea are propagated in a novel, multistep, proprietary, and patented process. From a single donor, we believe we have the potential to manufacture corneal endothelial cells to treat up to 1,000 recipient eyes. We believe our cell therapy procedure is designed to be considerably less complex, easier to learn and more efficient to perform than corneal transplantation. Post-operative recovery for cell therapy typically involves patients lying face down for three hours, as compared to patients typically lying on their backs for up to three days for corneal endothelial transplant procedures.

Pipeline

In Japan, early clinical research¹ followed by dose-ranging and confirmatory clinical trials have successfully demonstrated the safety, efficacy, and tolerability of our first-generation cell therapy product, Vyznova. We have received regulatory approval from Japan’s PMDA.

In the United States and Canada, we are currently conducting a Phase 1/2 trial for our lead product candidate, AURN001. Enrollment and dosing for this trial have been completed and we announced topline data in the fourth quarter of 2024.